Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of E7389 in previously treated advanced or metastatic breast cancer
2005-003656-35Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd. Primary endpoint: Primary Efficacy Endpoint. Started Dec 2005; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003656-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003656-35.